Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Seres Therapeutics (MCRB) FCF Margin: 2016-2025

Historic FCF Margin for Seres Therapeutics (MCRB) over the last 8 years, with Sep 2025 value amounting to 626.21%.

  • Seres Therapeutics' FCF Margin was N/A to 626.21% in Q3 2025 from the same period last year, while for Sep 2025 it was -21,839.25%, marking a year-over-year change of. This contributed to the annual value of -99.21% for FY2023, which is 324867.00% up from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' FCF Margin is 626.21%, which was down 89.04% from 5,711.65% recorded in Q1 2024.
  • Over the past 5 years, Seres Therapeutics' FCF Margin peaked at 5,711.65% during Q1 2024, and registered a low of -75,587.50% during Q4 2023.
  • Its 3-year average for FCF Margin is -17,390.53%, with a median of -7,699.69% in 2023.
  • As far as peak fluctuations go, Seres Therapeutics' FCF Margin plummeted by 6,980,771bps in 2023, and later surged by 2,116,223bps in 2024.
  • Seres Therapeutics' FCF Margin (Quarterly) stood at -740.08% in 2021, then crashed by 503,972bps to -5,779.79% in 2022, then crashed by 6,980,771bps to -75,587.50% in 2023, then spiked by 2,116,223bps to 5,711.65% in 2024, then reached 626.21% in 2025.
  • Its FCF Margin was 626.21% in Q3 2025, compared to 5,711.65% in Q1 2024 and -75,587.50% in Q4 2023.